These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 15709989)

  • 1. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.
    Korzenik JR; Dieckgraefe BK
    Aliment Pharmacol Ther; 2005 Feb; 21(4):391-400. PubMed ID: 15709989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sargramostim for active Crohn's disease.
    Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
    N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease.
    Magno P; Jiménez CE; Ortiz Z; Torres EA
    P R Health Sci J; 2010 Mar; 29(1):60-5. PubMed ID: 20222336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.
    Cassinotti A; Annaloro C; Ardizzone S; Onida F; Della Volpe A; Clerici M; Usardi P; Greco S; Maconi G; Porro GB; Deliliers GL
    Gut; 2008 Feb; 57(2):211-7. PubMed ID: 17895357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS; Markowitz J; Wyllie R
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infliximab therapy for Crohn's disease anoperineal lesions].
    Ouraghi A; Nieuviarts S; Mougenel JL; Allez M; Barthet M; Carbonnel F; Cosnes J; Gendre JP; Flourié B; Meurisse JJ; Quandalle P; Ernst O; Lemann M; Cortot A; Modigliani R; Colombel JF
    Gastroenterol Clin Biol; 2001 Nov; 25(11):949-56. PubMed ID: 11845044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lamprene in ano-perineal lesions of Crohn's disease. A retrospective study].
    Pinès AE; Cosnes J; Carbonnel F; Ngo Y; Beaugerie L; Gendre JP; Le Quintrec Y
    Ann Gastroenterol Hepatol (Paris); 1993; 29(4):155-63. PubMed ID: 8239487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
    Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ornidazole in the treatment of active Crohn's disease: short-term results.
    Triantafillidis JK; Nicolakis D; Emmanoullidis A; Antoniou A; Papatheodorou K; Cheracakis P
    Ital J Gastroenterol; 1996 Jan; 28(1):10-4. PubMed ID: 8743067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease.
    Vaughan D; Drumm B
    N Engl J Med; 1999 Jan; 340(3):239-40. PubMed ID: 9917236
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral butyrate for mildly to moderately active Crohn's disease.
    Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
    Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
    Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.